Last updated: July 31, 2025
Introduction
Patent KR20100036367, titled "Method for manufacturing a pharmaceutical composition containing a viral vector," was filed by Samsung Bioepis Co., Ltd., in South Korea. The patent focuses on biotechnological methods related to viral vector-based pharmaceutical compositions, primarily targeting gene therapy or vaccine applications. It addresses key aspects of viral vector production, stabilizing agents, and process conditions, aiming to improve yield, safety, and efficacy.
This analysis offers an in-depth understanding of the patent’s scope, claims, and its positioning within the broader pharmaceutical and biotechnological patent landscape in South Korea, highlighting its strategic importance for innovators and competitors.
Scope and Core Claims
Scope of the Invention
The patent primarily claims a method for preparing a viral vector suitable for therapeutic use. It encompasses:
- Manufacturing processes involving specific steps for producing viral vectors, such as adenoviruses.
- Use of stabilizers and excipients to enhance viral stability during production and storage.
- Optimized conditions for cell culture, purification, and virus harvesting.
- Addresses novel combinations of process parameters, emphasizing efficiency and safety.
The scope leans toward improving traditional viral vector manufacturing, ensuring higher titers, minimal contaminants, and stability during downstream processing.
Key Claims
The patent contains numerous claims—specifically, independent claims outline the core invention, with dependent claims elaborating on specific embodiments. Major claims include:
-
Claim 1: A method for producing a viral vector comprising cultivating host cells in a medium containing specific conditions, followed by purification steps, where the method employs particular stabilizers (e.g., sugars or amino acids) to enhance vector stability.
-
Claim 2: The method of claim 1, wherein the stabilizer is trehalose or sorbitol.
-
Claim 3: The process involves specific pH ranges (e.g., pH 7.2–7.6) during virus harvesting to optimize yield and stability.
-
Claim 4: A purification step involving filtration and chromatography techniques performed under controlled conditions to ensure purity.
-
Claim 5: Utilization of specific host cell lines, such as HEK293 or PER.C6, for higher productivity.
Other dependent claims refine process parameters, stabilizer concentrations, and culture conditions.
Patent protection covers both the methodology and the composition aspects, notably the inclusion of specific stabilizers and conditions that contribute to a more robust manufacturing process.
Patent Landscape Analysis
Technological Context in South Korea
South Korea hosts a vibrant biotech sector with a robust patent landscape for viral vector technology, driven by local giants like Samsung Bioepis and SK Bioscience, and international players. The development of viral vectors, particularly for COVID-19 vaccines like AstraZeneca's and Moderna’s, has accelerated IP filings.
Patent KR20100036367 sits within the broader gene therapy and vaccine production clusters. Its priority is leveraging process innovations to improve scalability, stability, and safety—critical factors in commercial manufacturing.
Competitive Patent Landscape
The patent landscape includes:
-
Global patents on vector design (e.g., US, EP, WO applications) with overlapping claims on stabilizers, cell culture methods, and purification techniques.
-
Regional patents in South Korea focusing on process specificities, such as stabilizer use, process parameters, or host cell modifications.
-
Key patentholders such as Merck, Vical, and local firms with extensive patent families on viral vector manufacturing.
KR20100036367 is positioned to cover process improvements that may circumvent existing patents, especially on stabilizer use and culture conditions, offering strategic freedom to operate.
Legal Status and Enforcement
The patent was granted in South Korea in 2010, with a 20-year term from filing. Its enforceability reinforces the holder’s position in the local market, particularly in the vaccine and gene therapy segments.
Moreover, the patent’s claims on manufacturing processes provide a barrier to entry for competitors, making process design around these claims a critical consideration in market strategy.
Implications for Innovators & Industry Players
-
For patent holders: The patent offers a strong foothold in process control, allowing exclusivity in specific viral vector manufacturing approaches.
-
For licensees: Companies must seek licensing or develop alternative processes that avoid infringement, possibly by altering stabilizer types, culture conditions, or purification methods outside the scope of these claims.
-
For researchers: The patent highlights promising areas for innovation—such as novel stabilizers or culture conditions—that might be outside the scope of existing claims.
-
Competitive landscape: The patent potentially blocks competitors from deploying similar stabilization strategies without licensing, affecting licensing negotiations, R&D directions, and patent strategies.
Conclusion & Strategic Recommendations
KR20100036367 demonstrates a comprehensive approach to optimizing viral vector manufacturing, crucial for vaccine and gene therapy markets. Its claims on stabilizers, culture conditions, and purification techniques are highly relevant, especially given the critical role these elements play in scalable and safe bioprocessing.
Responsibly navigating around this patent involves either licensing negotiations or developing alternative methods that explicitly differ in stabilizer use, process parameters, or vector design.
Key Takeaways
- Scope: Covers specific process steps and stabilizer use in viral vector manufacturing, emphasizing stability and yield.
- Claims: Focused on stabilizers like trehalose or sorbitol, process pH, and purification methods, forming a robust IP barrier.
- Patent Landscape: Positioned within a competitive South Korean biotech environment, with overlapping claims from global patent families.
- Market Impact: Vital for vaccine and gene therapy manufacturers in South Korea seeking to establish or expand production capabilities.
- Strategic Advice: Innovators should evaluate licensing options or explore alternative stabilizers and process conditions to avoid infringement.
FAQs
1. How does KR20100036367 impact viral vector manufacturing in South Korea?
It provides patent protection over specific stabilizers and process conditions, effectively securing exclusivity in those methods and influencing process development strategies.
2. Can competitors avoid infringement by altering stabilizers?
Yes, if they utilize different stabilizers or alternative process parameters outside the scope of the claims, they can mitigate infringement risks.
3. Are the claims limited to specific viral vectors?
The patent mainly discusses adenovirus vectors and general viral vectors; specific claims may specify particular virus types or cell lines.
4. What is the patent's enforceability in the South Korean biotech market?
As a granted patent with a 20-year term from filing, it is enforceable, giving the patent holder substantial market protection.
5. How does this patent relate to global developments in viral vector technology?
It reflects a localized but strategic subset of global viral vector IP, emphasizing process improvements like stabilizer use, contributing to the overall patent ecosystem in biomanufacturing.
References
[1] Korean Intellectual Property Office. Patent KR20100036367, titled "Method for manufacturing a pharmaceutical composition containing a viral vector," 2010.
[2] South Korean Patent Database. Summary of claims and legal status, 2023.
[3] World Intellectual Property Organization. Patent landscape reports on viral vector manufacturing technologies, 2022.
